Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × ARRY-334543 × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

pembrolizumab 12 Injections 12 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Capecitabine 8 senaparib 7 Nivolumab 7 Fluorodeoxyglucose F18 7 Bevacizumab 7 toripalimab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Cyclophosphamide 6 tislelizumab 5 fludarabine 4 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡